光声刺激疗法在关键试验中未能达到主要目标
Alzheimer's Light and Sound Stimulation Therapy Misses Main Goal in Pivotal Trial
一项针对轻中度阿尔茨海默病患者的HOPE试验显示,40 Hz光声刺激疗法在主要终点上未达预期,但在轻度患者亚组中显示出减缓认知和日常功能下降的趋势。
研究显示新型光声刺激疗法在轻度阿尔茨海默病患者中显示出潜在疗效,但总体未达主要终点。
— But gamma wave approach hints at slower decline in mild Alzheimer's disease
by Judy George, Deputy Managing Editor, MedPage Today
November 20, 2026 • 3 min read
A novel Alzheimer's therapy platform that delivered 40 Hz light and sound stimulation to engage gamma-frequency brain activity did not meet its primary endpoint, the HOPE pivotal study showed.
In the primary analysis population of 663 people with mild-to-moderate Alzheimer's, the change from baseline on a composite measure of Mini-Mental State Examination (MMSE) and Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores did not differ between those who used the Spectris stimulation goggles or sham at 12 months, reported Marwan Sabbagh, MD, of the Barrow Neurological Institute in Phoenix.
Secondary endpoints in the overall study population also showed no significant differences. However, a prespecified subgroup analysis of 395 people with mild Alzheimer's disease (MMSE scores of 21-28 on the 30-point scale) showed favorable results for the device on some measures, Sabbagh said at the Clinical Trials on Alzheimer's Disease conference in Boston.
In the mild subgroup, the device was associated with a 55.8% slowing of decline in ADCS-ADL scores (nominal P=0.016) and a 46.8% slowing of decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores (nominal P=0.004), Sabbagh noted.
Results in the moderate subgroup (MMSE scores of 15-20) did not favor the device, and some outcomes nominally favored sham.
The difference in outcomes between mild and moderate disease suggests that earlier intervention may be key to clinical benefit, observed Laura Nisenbaum, PhD, interim chief science officer at the Alzheimer's Drug Discovery Foundation in New York City, which provided funding for the trial.
"While the HOPE study did not meet its primary endpoint, the signal in the mild Alzheimer's subgroup raises important questions that are worth exploring further," Nisenbaum said. "Daily function is what patients and families tell us matters most, so it will be important to see whether the early signs of slower decline on that measure in people with mild Alzheimer's hold up as more data become available."
The device delivers audiovisual stimulation intended to evoke steady-state gamma oscillations across broad cortical regions, Sabbagh explained. "Spectris was developed as a non-invasive, home-use investigational medical device that delivers daily 1-hour treatment sessions," he said.
Earlier research showed that sensory-evoked 40 Hz neural activity engages brain mechanisms essential for cognition and daily function, he added.
The HOPE trial evaluated the device in participants who had baseline MMSE scores of 15-28 and Alzheimer's biomarker confirmation. Participants were randomized within stratified mild and moderate disease subgroups.
The primary outcome was the integrated Alzheimer's Disease MMSE and ADCS-ADL Rating Scale, an equally weighted composite of global cognition (MMSE) and daily function (ADCS-ADL) scores, Sabbagh said.
In the overall study population, adverse device effects were reported in 18.3% of participants who received active treatment and 15.5% who received sham. The most common were headache, tinnitus, fatigue, dizziness, and ear pain. Seizures occurred in 0.9% of the active treatment group.
The gamma wave approach to treating Alzheimer's disease was first discovered in 2014 at the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology (MIT). Executives at Cognito Therapeutics, an MIT spin-off, said they will pursue FDA approval for the 40 Hz light and sound stimulation device based on the nominally significant benefits seen in the mild Alzheimer's population.
An open-label extension of the HOPE trial is ongoing.
来源:MedPage Today · medpagetoday.com